Carmen Balañá

10.0k total citations · 1 hit paper
119 papers, 2.7k citations indexed

About

Carmen Balañá is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Carmen Balañá has authored 119 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Genetics, 58 papers in Pulmonary and Respiratory Medicine and 41 papers in Oncology. Recurrent topics in Carmen Balañá's work include Glioma Diagnosis and Treatment (71 papers), Brain Metastases and Treatment (25 papers) and Cancer Genomics and Diagnostics (16 papers). Carmen Balañá is often cited by papers focused on Glioma Diagnosis and Treatment (71 papers), Brain Metastases and Treatment (25 papers) and Cancer Genomics and Diagnostics (16 papers). Carmen Balañá collaborates with scholars based in Spain, France and United States. Carmen Balañá's co-authors include Olivier Chinot, Kirsten Hopkins, Michael Weller, Guido Reifenberger, Jörg C. Tonn, Didier Frappaz, Roger Stupp, Wolfgang Wick, Gaspar Reynés and Zvi Ram and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Carmen Balañá

107 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

2014 568 citations Michael Weller, Kirsten Hopkins et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carmen Balañá Spain	25	1.2k	848	839	774	644	119	2.7k
Benoît Lhermitte France	18	1.1k 0.9×	702 0.8×	821 1.0×	710 0.9×	647 1.0×	77	2.5k
Magalie Hilton Switzerland	12	1.5k 1.2×	1.0k 1.2×	692 0.8×	775 1.0×	665 1.0×	24	2.6k
Teri Kreisl United States	17	1.7k 1.4×	713 0.8×	722 0.9×	443 0.6×	591 0.9×	31	2.4k
Michel Fabbro France	34	778 0.6×	723 0.9×	658 0.8×	1.1k 1.4×	511 0.8×	187	3.1k
Pierre-Yves Dietrich Switzerland	13	1.5k 1.2×	536 0.6×	942 1.1×	624 0.8×	569 0.9×	14	2.5k
R. Rampling United Kingdom	19	1.3k 1.1×	681 0.8×	565 0.7×	500 0.6×	452 0.7×	30	2.1k
Jennifer S. Yu United States	24	823 0.7×	826 1.0×	1.2k 1.4×	869 1.1×	569 0.9×	91	2.6k
Lyndon Kim United States	19	1.6k 1.3×	633 0.7×	756 0.9×	412 0.5×	554 0.9×	42	2.4k
David Piccioni United States	25	733 0.6×	861 1.0×	821 1.0×	998 1.3×	1.1k 1.8×	94	2.7k
Jeannette M. Dowell United States	18	1.4k 1.1×	692 0.8×	1.3k 1.6×	1.1k 1.4×	785 1.2×	19	3.2k

Countries citing papers authored by Carmen Balañá

Since Specialization

Citations

This map shows the geographic impact of Carmen Balañá's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen Balañá with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen Balañá more than expected).

Fields of papers citing papers by Carmen Balañá

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen Balañá. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen Balañá. The network helps show where Carmen Balañá may publish in the future.

Co-authorship network of co-authors of Carmen Balañá

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen Balañá. A scholar is included among the top collaborators of Carmen Balañá based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen Balañá. Carmen Balañá is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Muñoz‐Mármol, Ana M, Bárbara Meléndez, Ainhoa Hernández, et al.. (2025). Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib. Cancers. 17(3). 375–375. 2 indexed citations

Pineda, Estela, Ainhoa Hernández, Marta Doménech, et al.. (2024). The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation. Cancers. 16(4). 735–735. 1 indexed citations

Balañá, Carmen, et al.. (2023). Unlocking Bevacizumab’s Potential: rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients. Cancers. 16(1). 161–161. 3 indexed citations

Salgado, María Ángeles Vaz, Sonia Del Barco, Juan Manuel Sepúlveda-Sánchez, et al.. (2023). 501O Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial. Annals of Oncology. 34. S393–S393. 1 indexed citations

Cirauqui, Beatriz, Teresa Morán, Anna Estival, et al.. (2020). Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management. Case Reports in Oncology. 13(1). 130–138. 2 indexed citations

Balañá, Carmen, María Buxó, Gerard Blasco, et al.. (2019). Impact of Dexamethasone on Metabolic Profile and Survival in Glioblastoma. Universitat de Girona Digital Repository (Universitat de Girona). 4(1). 2 indexed citations

Fizazi, Karim, Aline Maillard, Nicolas Penel, et al.. (2019). A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Annals of Oncology. 30. v851–v851. 158 indexed citations

Domènech, Sira, Juan Garcia, Fidel Ángel Núñez, et al.. (2018). C-Methionine PET (Met-PET) for a diagnosis algorithm for pseudoprogression (PsP), radiations necrosis (RN) and progression (P) after an indeterminate magnetic resonance imaging (MRI) in glioblastoma (GBM).. Journal of Clinical Oncology. 36(15_suppl). e14039–e14039. 1 indexed citations

Losa, Ferrán, L. Iglesias, Victòria Fusté, et al.. (2018). 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clinical & Translational Oncology. 20(11). 1361–1372. 30 indexed citations

10.

Matías‐Guiu, Xavier, Victòria Fusté, L. Iglesias, et al.. (2018). Consenso 2018 de la Sociedad Española de Anatomía Patológica y la Sociedad Española de Oncología Médica sobre el diagnóstico y tratamiento del cáncer de origen desconocido. Revista Española de Patología. 52(1). 33–44.

11.

Martinez‐García, Maria, Estela Pineda, Sonia Del Barco, et al.. (2016). Feasibility and efficacy of concomitant chemoradiation (Ch-RT) in the management of newly diagnosed elderly glioblastoma (GB) patients: Results from the GLIOCAT study.. Journal of Clinical Oncology. 34(15_suppl). 2045–2045.

12.

Molina, David, Julián Pérez-Beteta, Alicia Martínez‐González, et al.. (2016). Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS ONE. 11(8). e0161484–e0161484. 10 indexed citations

13.

Balañá, Carmen, et al.. (2015). Economic Analysis Of Epicup, An Epigenetic Test To Predict The Tissue Of Origin In Cancer Of Unknown Primary Site, From The Spanish Nhs Perspective. Value in Health. 18(7). A356–A357. 1 indexed citations

14.

Sepúlveda-Sánchez, Juan Manuel, Cristóbal Belda-Iniesta, Miguel Gil‐Gil, et al.. (2015). A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Clinical & Translational Oncology. 17(9). 743–750. 11 indexed citations

15.

Cloughesy, Timothy F., Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.. (2015). Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. Journal of Clinical Oncology. 33(15_suppl). 2015–2015. 26 indexed citations

16.

Villà, S., et al.. (2013). Patterns of relapse in glioblastoma after neoadjuvancy and radiation therapy. Reports of Practical Oncology & Radiotherapy. 18. S195–S195. 1 indexed citations

17.

Balañá, Carmen, S. Villà, & Pilar Teixidor. (2011). Evolution of care for patients with relapsed glioblastoma. Expert Review of Anticancer Therapy. 11(11). 1719–1729. 4 indexed citations

18.

Rosell, Rafael, Enriqueta Felip, Rosario García‐Campelo, & Carmen Balañá. (2004). The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer. 46(2). 135–148. 32 indexed citations

19.

Rosell, Rafael, Cristina Martín, & Carmen Balañá. (1999). Ifosfamide in non-small-cell lung cancer. Annals of Oncology. 10. S25–S28. 3 indexed citations

20.

Villar, Ana, Enrique Aranda, Carmen Balañá, et al.. (1991). Fractionated high doses (HD) of epirubicin (E) in adenocarcinoma of the lung (ADL). Lung Cancer. 7. 122–122. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact